ABE9-SpRY and Precision Mouse Models
Research question
The study asks whether an ABE9-SpRY fusion can address important limitations of earlier adenine base editors: restricted target-site compatibility, bystander substitutions within the editing window, and unintended activity at other genomic sites. The broader motivation is to create disease-relevant point-mutation models without relying on double-strand DNA breaks or donor DNA, which can be associated with indels and other unwanted genomic outcomes. These aims and the reported comparisons are described in the authors’ Scientific Reports study.
Conceptual study design
Conceptually, the investigators combined two editor features: the ABE9 variant and the PAM-flexible SpRY Cas9 nickase. They evaluated the resulting editor at selected mouse-embryo targets, compared its performance with ABE8e-SpRY, and examined several dimensions of editing outcome rather than relying only on the intended nucleotide conversion.
- Targeted A-to-G substitutions were assessed at four mouse loci.
- Founder animals were examined to determine whether the intended edits could be recovered in adult mice.
- Product purity and bystander editing were evaluated, including under pooled-guide conditions.
- Potential off-target activity was assessed at predicted DNA sites and with an orthogonal R-loop assay.
- A proof-of-concept comparison was also made at one endogenous locus in human induced pluripotent stem cells.
This is a comparative, locus-focused design. It can test whether the new editor improves outcomes under the study’s selected conditions, but it cannot by itself demonstrate uniform behavior across the genome, species, cell states, or disease-associated variants.
Reported findings
The authors report that ABE9-SpRY generated three of the four targeted A-to-G substitutions in mouse embryos. The reported editing efficiency reached up to 96% in individual adult founder mice. These results support the feasibility of recovering intended point-mutation founders, while the uneven success across targets also illustrates that performance remains sequence-dependent.
Relative to ABE8e-SpRY, ABE9-SpRY was reported to produce fewer off-target events at the predicted DNA sites examined and in the orthogonal R-loop assay. The study also reports improved product purity in mouse embryos when guide RNAs were pooled, as well as at one endogenous locus in human induced pluripotent stem cells. In the authors’ interpretation, these findings support greater precision and broader target-site flexibility at the loci tested.
What the evidence supports—and does not
Finding: ABE9-SpRY performed favorably against ABE8e-SpRY in the reported comparisons, with high intended-editing values at some mouse targets and fewer detected unwanted events in the assays used.
Interpretation: The results suggest that the editor may be useful for constructing selected point-mutation models where bystander editing is a major concern. They do not establish that the approach is universally bystander-free, nor that predicted-site analysis and an orthogonal assay exclude all unintended genomic changes.
The title’s reference to “bystander free” should therefore be read in the context of the tested editing products and loci, rather than as a claim of absolute genome-wide absence of bystander substitutions. The supplied study summary itself emphasizes sequence dependence, which is an important boundary on generalization.
Limitations and applicability boundaries
- Limited locus coverage: The reported mouse evaluation involved four targeted A-to-G changes, so the findings may not represent the full range of sequence contexts or editing windows.
- Incomplete off-target scope: Predicted DNA sites and an orthogonal R-loop assay provide useful evidence, but they are not equivalent to an exhaustive assessment of every possible unintended genomic or cellular consequence.
- Cross-system limits: The human-cell result was described as a proof of concept at a single endogenous locus. It should not be generalized to all human induced pluripotent stem-cell targets or disease models.
- Outcome interpretation: High intended-editing percentages do not alone establish biological normality, stable inheritance, absence of mosaicism, or suitability for a particular disease-model application.
- Comparative rather than definitive evidence: The study supports a relative advantage over ABE8e-SpRY in the reported assays; it does not prove superiority over every base editor or editing strategy.
Provenance and unrelated reagent context
Proteinase K is not part of the cited ABE9-SpRY evidence. APExBIO describes its Proteinase K product as a recombinant broad-spectrum serine protease used conceptually for protein hydrolysis in molecular biology, enzyme contaminant removal for DNA prep, and as a genomic DNA isolation enzyme with attention to DNA integrity preservation during protein digestion. That supplier description is a separate product claim, not evidence that Proteinase K was used in the base-editing study or that it affects editing precision.
Overall assessment
The study provides promising comparative evidence that ABE9-SpRY can combine PAM flexibility with improved editing-product purity and fewer detected off-target events than ABE8e-SpRY in the tested settings. Its strongest contribution is proof of concept for selected mouse point-mutation models, reinforced by a limited human-cell demonstration. The evidence remains appropriately bounded by the small set of loci, sequence dependence, assay coverage, and the distinction between reduced detected bystander or off-target activity and complete absence of unintended effects.